The factories of EIPICO Pharmaceuticals – the largest ACDIMA’s pharmaceutical company – received an Italian delegation of Dr. Carlo Riccini , Deputy general Director of Farmindustria ” the Association of Italian Pharmaceutical Companies ” , Dr. Camilla Borghese, President of the Italian Biochemistry Institute ( G. Lorenzini ) and Mr. Vincenzo Cali, Commissioner of the Italian Trade Agency, trade promotion section of the Italian embassy in Cairo.
The delegation was received by Dr. Olfat Ghorab, Chairman of ACDIMA of and Dr. Ahmed Kelani, Chairman of the Board of Directors and Managing Director of EIPICO Pharmaceuticals Company, where Dr. Olfat presented the capabilities and diversity of the ACDIMA companies, and the scopes of full coordination between these companies in providing all important medicines to citizens, as well as the cooperation that took place to support all presidential initiatives in the field of health care, the most important of which is eliminating the C virus.
Dr. Ahmed Kelani gave a detailed presentation of the capabilities of EIPICO and its current and future projects, the most important of which is the project to establish the Arab Company for Pharmaceutical Active Ingredients (ARAB API), and the establishment of the first multi-purpose factory in the Middle East for the production of pharmaceutical raw materials, in the economic zone of Ain Sokhna, The project land was allocated on an area of 85 thousand square meters. which is being implemented in cooperation with ACDIMA Company and the Economic Zone Investment Company – owned by the General Authority for the Suez Canal Economic Zone – with investments amounting to 100 million dollars. The capital contribution shares currently amount to: ACDIMA 60%, EIPICO 30%, and the Suez Canal Economic Authority 10%.
Most probably these share percentages once the detailed technical studies of the project are accomplished , As some of Arab & other investors have expressed interest in contributing to the project.
Dr. Kelani also presented the latest developments in the implementation of the EIPICO3 factory project. – The one & only of its kind in Egypt and the Middle East , to fully manufacturing Biosimilars & Biologicals starting from the cell all the way up to the finished product. And the possibility of future co-operation with Italian companies in manufacturing Bio-Pharmaceutical products.
The factory construction is currently almost finished, on more than 10,000 square meters with investments of $100 million, Passing on EIPICO multiple capabilities in producing all traditional and non-traditional pharmaceutical forms and its position as the largest pharmaceutical company in the local market in terms of the number of units sold, as well as the first ranked company to export medicine in Egypt, stressing that EIPICO obtained the GMP quality certificate from Romania- is one of the European Union countries – that facilitates the penetration of EIPICO products into a number of European countries and enables it in the future, in cooperation with Italian companies, to be present in Italian markets.
Dr. Olfat Gharab drew attention to the opportunities and possibilities of joint cooperation between ACDIMA companies and Italian, as ACDIMA ‘s company can be a hub for Italian pharmaceutical products to penetrate Africa & MENA region markets through Co – manufacturing of Italian in Egypt , taking in consideration ACDIMA’s companies are distinguished by the great diversity of capabilities and using Up-to-date of manufacturing and quality control technology.
Dr. Ahmed Kelani emphasized the potential opportunities of cooperation through the Arab Raw Materials Company API ARAB – and after establishing the project – in the field of manufacturing a number of pharmaceutical raw materials produced by Italian companies and marketing them in Egypt, the Middle East and Africa, in addition to many other countries, especially since the API ARAB factory will be the first in the region, as a “Multi-Purpose” for producing many pharmaceutical raw materials, The Italian side showed special interest in this scope of cooperation.
On the other hand, Dr. Camila has expressed a special interest in manufacturing a group of sterile antibiotic preparations in EIPICO factories the both sides has agreed to start studying this issue in full details.
This visit comes on the sidelines of the visit of the Italian Minister of Health to Egypt, during which he was accompanied by a significant delegation of investors and pharmaceutical manufacturers in Italy.
